🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06141538
Starting soon Observational

Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)

NCT06141538 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Observational
Started
2024-12-31
Last updated
2024-04-04

Condition(s) studied

Atrial FibrillationIntracardiac Thrombus

Investigational drug(s) / intervention(s)

Observational; No Interventions were given.

Observational; No Interventions were given.: Observational; No Interventions were given.

Study summary

This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years old, age ≤80 years old * Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter * Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy Exclusion Criteria: * Echocardiography confirmed valvular heart disease * Contraindications to anticoagulants * Patients with the previous history of hemorrhagic stroke * Low platelet count or functional platelet defects * Congenital or acquired coagulation or bleeding disorders * Abnormal liver function (liver enzymes \>2 times the upper limit) * Renal failure (endogenous creatinine clearance \<30ml/min) * Surgery was planned within the intended study time or had been operated within 30 days before the study * Other comorbidities that can cause bleeding, such as tumors * Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators * Patients are currently participating in other clinical studies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Xian Jiantong University Xi'an Shaanxi

More First Affiliated Hospital Xi'an Jiaotong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06141538 on ClinicalTrials.gov ↗ ← All trials in China